Prosecution Insights
Last updated: November 04, 2026
Application No. 18/573,387

INTERLEUKIN 15 VARIANTS

Non-Final OA §112
Filed
Dec 21, 2023
Priority
Jun 23, 2021 — EU 21181261.5 +1 more
Examiner
MERTZ, PREMA MARIA
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sotio Biotech A S
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
556 granted / 774 resolved
+11.8% vs TC avg
Strong +35% interview lift
Without
With
+34.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
42 currently pending
Career history
795
Total Applications
across all art units

Statute-Specific Performance

§101
6.8%
-33.2% vs TC avg
§103
23.7%
-16.3% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
46.0%
+6.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 774 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election with traverse of Group I (claims 1, 3-11, 16, 18, and new claim 22 (8/24/2026) drawn to an interleukin-15 (IL- 15) variant comprising amino acid substitutions at position G78 and at position N79 of a mature human IL-15), in the reply filed on 8/24/2026 is acknowledged. The traversal is on the ground(s) that CN 112552391A (CN '391) discloses an IL-15 variant comprising the G78A substitution, however, CN '391 does not disclose nor suggest that amino acid substitutions at position 78 in combination with a substitution at position 79 in the mature IL-15 sequence would result in the unexpected technical effects, as presented in the present specification, CN '391 does not teach or suggest a number of required elements of the present claims, the skilled artisan would have had no reason to make the selections or substitutions required to arrive at the present claims, and could not have predicted that the present combination of features would provide the benefits as instantly disclosed, the claims as set forth are novel and inventive over the cited prior art, and therefore, all of the claims comprise a common unique special technical feature and should be examined together. Additionally, Applicant argues that in view of the substantial commonality of the subject matter of all of the claims, the search for the subject matter of one of these groups will necessitate a search of the subject matter of the other groups, no substantial burden is therefore seen in consideration of these species in a single application, and examination of the non-elected species with the elected species provides efficiency in early determination of the full scope of patent protection to be afforded in this technology, which is of great benefit to the public. This is not found persuasive because due to the presence of a defective Sequence Listing submitted by Applicant, the different Groups cannot be examined. Once the Sequence Listing is compliant, the Examiner may consider joining the other Groups. Furthermore, with respect to the product claims of Group I and rejoinder with the corresponding method of treatment claims (see In re Ochiai (37 USPQ2d 1127 (Fed. Cir. 1995)), in which a new, unobvious material is used in a known process, Ochiai determined that a process was free of the prior art if it employed a product, which was free of the prior art. However, only if the product claims of Group I are found allowable, the subject matter of the corresponding method claims will be rejoined with the process claims, if the process claims are of the same scope as the allowable product claims. Elected claims 1, 3-11, 16, 18, and new claim 22 which encompass the elected Group are under consideration by the Examiner. The requirement is still deemed proper and is therefore made FINAL. Claims 12-15, 17, 19-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Information Disclosure Statement 3. The information disclosure statements (IDS) submitted on 8/25/2026, 8/26/25, 12/21/23, are in compliance with the provisions of 37 CFR 1.97 and have been considered by the examiner. Applicant is reminded of their duty to disclose to the Office all information known to the person to be material to patentability as defined in 37 CFR 1.56. As stated therein, “[e]ach individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section”. Sequence Rule Compliance REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES Items 1) and 2) provide general guidance related to requirements for sequence disclosures. 37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted: In accordance with 37 CFR 1.821(c)(1) via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification as required by 37 CFR 1.823(b)(1) identifying: the name of the ASCII text file; ii) the date of creation; and iii) the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(1) on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(8) and 37 CFR 1.823(b)(1) in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(2) via the USPTO patent electronic filing system as a PDF file (not recommended); or In accordance with 37 CFR 1.821(c)(3) on physical sheets of paper (not recommended). When a “Sequence Listing” has been submitted as a PDF file as in 1(c) above (37 CFR 1.821(c)(2)) or on physical sheets of paper as in 1(d) above (37 CFR 1.821(c)(3)), 37 CFR 1.821(e)(1) requires a computer readable form (CRF) of the “Sequence Listing” in accordance with the requirements of 37 CFR 1.824. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via the USPTO patent electronic filing system as a PDF, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the PDF copy and the CRF copy (the ASCII text file copy) are identical. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or read-only optical disc, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the paper or read-only optical disc copy and the CRF are identical. Specific deficiencies and the required response to this Office Action are as follows: Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: Specific deficiency - This application fails to comply with the requirements of 37 CFR 1.831-1.834 because the “Sequence Listing XML,” as a separate part of the disclosure, is defective. Refer to document “Sequence Listing in Computer Readable Format is Defective” dated 12/26/2023. ST.25 has been filed when ST.26 is required. Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: Required response - Applicant must provide: • A replacement “Sequence Listing XML” part of the disclosure, as described above submitted in accordance with either item 1. or 2.; together with o A statement that identifies the location of all additions, deletions or replacements of sequence information relative to the replaced “Sequence Listing XML” as required by 37 CFR 1.835(b)(3); o A statement that indicates support for the replacement “Sequence Listing XML” in the application, as filed, as required by 37 CFR 1.835(b)(4); and o A statement that the replacement “Sequence Listing XML” includes no new matter as required by 37 CFR 1.835(b)(5). AND • A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, inserting the required incorporation by reference paragraph as required by 37 CFR 1.835(b)(2), consisting of: o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); o A copy of the amended specification without markings (clean version); and o A statement that the substitute specification contains no new matter. Claim Rejections - 35 USC § 112(a), written description 5. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 5a. Claims 1, 3-11, 16, 18, and 22, are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant has claimed an interleukin-15 (IL-15) variant comprising amino acid substitutions at position G78 and at position N79 of a mature human IL-15, wherein the IL- 15 variant comprises the amino acid substitutions G78A, G78V, G78L or G781, and N79Q, N79H or N79M. There is no written description for every and all IL-15 variants as recited in claim 1 in the absence of the recitation of an amino acid sequence template for the IL-15 variant. Claim 8 recites “a conjugate comprising an IL-15 variant of claim 1, wherein the conjugate further comprises the sushi domain of an IL-15Rα or a derivative thereof”. Claim 9 recites “a fusion protein comprising an IL-15 variant of claim 1, wherein in the fusion protein further comprises the sushi domain of an IL-15Rα or a derivative thereof, a targeting moiety, and/or a half-life extending moiety.” Claim 11 recites “the fusion protein of claim 9, wherein the targeting moiety is an antibody or functional variant thereof.” The guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, § 1 "Written Description" Requirement make clear that if a claimed genus does not show actual reduction to practice for a representative number of species, then the Requirement may be alternatively met by reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the genus (Federal Register, Vol. 66, No. 4, pages 1099-1111, January 5, 2001, see especially page 1106 column 3). In Amgen Inc. v. Sanofi, 124 USPQ2d 1354 (Fed. Cir. 2017), relying upon Ariad Pharms., Inc. v. Eli Lily & Co., 94 USPQ2d 1161 (Fed Cir. 2010), the following is noted. To show invention, a patentee must convey in its disclosure that it “had possession of the claimed subject matter as of the filing date. Demonstrating possession “requires a precise definition” of the invention. To provide this precise definition” for a claim to a genus, a patentee must disclose “a representative number of species within the scope of the genus of structural features common to the members of the genus so that one of skill in the art can visualize or recognize the member of the genus” (see Amgen at page 1358). In The Regents of the University of California v. Eli Lilly (43 USPQ2d 1398-1412) 19 F. 3d 1559, the court held that disclosure of a single member of a genus (rat insulin) did not provide adequate written support for the claimed genus (all mammalian insulins). In this same case, the court also noted: “A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is. See Fiers, 984 F.2d at 1169-71, 25 USPQ2d at 1605-06 (discussing Amgen). It is only a definition of a useful result rather than a definition of what achieves that result. Many such genes may achieve that result. The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming rejection because the specification does “little more than outlin [e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material.” The court has further stated that “Adequate written description requires a precise definition, such as by structure, formula, chemical name or physical properties, not a mere wish or plan for obtaining the claimed chemical invention.” Id. at 1566, 43 USPQ2d at 1404 (quoting Fiers 984 F.2d at 1171, 25 USPQ2d at 1606). Also see Enzo-Biochem v. Gen-Probe 01-1230 (CAFC 2002). Further, recent court cases have indicated that recitation of an antibody which has specific functional properties in the absence of knowledge of the antibody sequences that give rise to said functional properties do not satisfy the requirements for written description. See for example AbbVie Deutschland GmbH v. Janssen Biotech. Inc. 759 F.3d 1285 (Fed. Cir. 2014) as well as Amgen v. Sanofi. (Fed Cir, 2017-1480. 10/5/2017). Indeed, in Amgen the court indicates that that it is improper to allow patentees to claim antibodies by describing something that is not the invention, i.e. the antigen, as knowledge of the chemical structure of an antigen does not give the required kind of structure-identifying information about the corresponding antibodies, with the antibody-antigen relationship be analogized as a search for a key on a ring with a million keys on it. Also, it is not enough for the specification to show how to make and use the invention, i.e., to enable it (see Amgen at page 1361). An adequate written description must contain enough information about the actual makeup of the claimed products – “a precise definition, such as structure, formula, chemic name, physical properties of other properties, of species falling with the genus sufficient to distinguish the gene from other materials”, which may be present in “functional terminology when the art has established a correlation between structure and function” (Amgen page 1361). In the instant case, the specification on page 7, lines 36-37, page 8, lines 1-16, discloses: “An "antibody variant" or "antibody functional variant", as used herein, relates to antibodies with modifications for e.g., modulating their effector functions, modulating the antibody stability and in vivo half-life and/or inducing heterodimerization of the antibody Fc domains. Such variants may be achieved by mutations and/or posttranslational modifications. Antibody variants also include antibody heavy chains with truncation of the N-terminal lysine on one or preferably both heavy chains. Other included variations are N- or C-terminal tags of the heavy and/or light chains for chemical or enzymatic coupling to other moieties such as dyes, radionuclides, toxins or other binding moieties. Further, antibody variants may comprise chemical modifications, modifications of their glycosylation or substitutions with artificial amino acids for chemical linkage to other moieties. Antibody variant, as used herein, also relates to immunoglobulin gamma (IgG)-based bispecific antibodies that potentially recognize two or more different epitopes. Various formats of bispecific antibodies are known in the art, e.g. reviewed by Godar et al. (2018) and Spiess et al. (2015). Bispecific formats according to this invention include an Fc domain. With respect to the immunocytokines of the inventions, two RLI conjugates may, if not otherwise linked to a moiety, be either fused to the C-terminus of both light chains or to the C-terminus of both heavy chains; alternatively, one RLI conjugate may be fused to the C-terminus of one heavy chain for heterodimeric bispecific formats, or to the heavy chain or one light chain of heterodimeric bispecific formats with different light chains. Antibody functional variants are capable of binding to the same epitope or target as their corresponding non-modified antibody.” However, no structure for functional variants of antibodies as set forth in the claim have been described. As such, the structure required of the desired antibody as set forth in claim 11, such that it has all of the desired functions is not disclosed in the specification as filed. Applicant is reminded that the courts have long ruled that “Possession may not be shown by merely describing how to obtain possession of members of the claimed genus or how to identify their common structural features.” See University of Rochester. 358 F.3d at 927, 69 USPQ2d at 1895. As such, disclosure of a screening assay to test for functional properties of an antibody does not provide evidence of possession of the antibody itself. It is well established in the art that the formation of an intact antigen-binding site requires the association of the three different complementarity determining regions, heavy chain CDR 1, 2 and 3, which provide the majority of the contact residues for the binding of the antibody to its target epitope. The amino acid sequences and conformations of each of the CDRs are critical in maintaining the antigen binding specificity and affinity, which is characteristic of the parent immunoglobulin (Janeway et al., 1997, see entire selection). It is also known that single amino acid changes in a CDR can abrogate the antigen binding function of an antibody (Rudikoff et al., 1982, see entire document, particularly the abstract and the middle of the left column of page 1982). Indeed, in AbbVie Deutschland GmbH v. Janssen Biotech. Inc. 759 F.3d 1285 (Fed. Cir. 2014) the court ruled that all of the antibodies disclosed by AbbVie were all structurally similar as they were variants of a starting antibody named Joe9 and therefore did not serve to inform artisans as to the breadth of structures which had the recited function of cytokine binding. In the instant application, the instant claims recite antibodies to be used in the claimed methods while the specification does not disclose structures which necessarily have the requisite functions. The instant specification fails to disclose sufficient structural information to indicate to artisans that Applicant had possession of functional variants of the desired antibodies. Therefore, the broad genus of functional variants of antibodies recited in Applicant’s claimed product lacks adequate written description because there does not appear to be sufficient correlation between the structure of the antibodies in question and their recited functional activities. As such a skilled artisan would reasonably conclude that Applicant was not in possession of the recited genus of antibodies in the claimed fusion protein recited in claim 11, and thus logically could not be in possession of such antibodies at the time the instant application was filed. Therefore, there is insufficient written description for the genus of antibodies having the claimed “limitations” at the time the invention was made and as disclosed in the specification as filed under the written description provision of 35 USC 112(a). Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115). As set forth in Amgen v. Sanofi, knowing the structure of what is being bound does not provide knowledge of the structure of the antibody that is being claimed. It should also be noted that the USPTO has released a Memo on the Clarification of Written Description Guidance For Claims Drawn to Antibodies and Status of 2008 Training Materials, 02/22/2018. See https://www.uspto.gov/sites/default/files/documents/amgen_22feb2018.pdf. This Memo clarifies the applicability of USPTO guidance regarding the written description requirement of 35 U.S.C. § 112(a) concerning the written description requirement for claims drawn to antibodies and states: “In view of the Amgen decision, adequate written description of a newly characterized antigen alone should not be considered adequate written description of a claimed antibody to that newly characterized antigen, even when preparation of such an antibody is routine and conventional”. Thus, the claims lack adequate written description for “functional variants” of antibodies as recited in claim 11. With respect to “derivative” of IL-15Rα” as recited in claim 8-9, Applicant has not provided written description for such “derivatives”. Furthermore, claims 8-9, do not require that the “IL-15Rα derivative” possess any particular conserved structure, or other distinguishing feature. To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, and any combination thereof. In this case, the only factor present in the claim that is sufficiently disclosed is a recitation of a desired activity. The specification does not identify any particular portion of the structure, nor does it provide a disclosure of structure/function correlation. The distinguishing characteristics of the claimed genus for the antigens or the targeting means are not described. Accordingly, the specification does not provide adequate written description of the claimed genus of antigens or targeting means. To satisfy the written-description requirement, the specification must describe every element of the claimed invention in sufficient detail so that one of ordinary skill in the art would recognize that the inventor possessed the claimed invention at the time of filing. Vas-Cath, 935 F.3d at 1563; see also Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572 [41 USPQ2d 1961] (Fed. Cir. 1997) (patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that “the inventor invented the claimed invention”); In re Gosteli, 872 F.2d 1008, 1012 [10 USPQ2d 1614] (Fed. Cir. 1989) (“the description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed”). Thus, an applicant complies with the written-description requirement “by describing the invention, with all its claimed limitations, not that which makes it obvious,” and by using “such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.” Lockwood, 107 F.3d at 1572. See University of Rochester v. G.D. Searle & Co., 68 USPQ2d 1424 (DC WNY 2003) and University of Rochester v. G.D. Searle & Co. et al. CAFC [(03-1304) 13 February 2004]. In University of Rochester v. G.D. Searle & Co. a patent directed to method for inhibiting prostaglandin synthesis in human host using an unspecified compound, in order to relieve pain without side effect of stomach irritation, did not satisfy written description requirement of 35 U.S.C. §112, since the patent described the compound's desired function of reducing activity of the enzyme PGHS-2 without adversely affecting PGHS-1 enzyme activity, but did not identify said compound, since invention consists of performing “assays” to screen compounds in order to discover those with desired effect. The patent did not name even one compound that assays would identify as suitable for practice of invention, or provide information such that one skilled in art could identify suitable compound. And since specification did not indicate that compounds are available in public depository, the claimed treatment method cannot be practiced without compound. Thus the inventors cannot be said to have “possessed” claimed invention without knowing of a compound or method certain to produce compound. Thus said patent constituted an invitation to experiment to first identify, then characterize, and then use a therapeutic a class of compound defined only by their desired properties. Therefore, the full breadth of the claims fails to meet the written description provision of 35 U.S.C. §112, first paragraph. In the instant case, for example, Applicants have failed to describe which “IL-15Rα derivatives” are encompassed by the claims. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision. Claim Rejections - 35 USC § 112(b) 6. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 6a. Claims 1, 3-11, 16, 18, and 22 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1, lines 1-4, is vague and indefinite because it recites "an interleukin-15 (IL-15) variant comprising amino acid substitutions at position G78 and at position N79 of a mature human IL-15, wherein the IL- 15 variant comprises the amino acid substitutions G78A, G78V, G78L or G781, and N79Q, N79H or N79M”. There is no amino acid sequence recited in the claims, therefore the claim is unclear. This rejection affects all dependent claims 3-11, 16, and 18 and independent new claim 22. This rejection can be obviated by reciting the specific SEQ ID NO for which there is a basis in the instant specification. Claim 5 is vague and indefinite for several reasons. Claim 5, line 2, is vague and indefinite because it recites “substantially” and the metes and bounds of this term are unclear. How much do the “amino acid substitutions do not substantially reduce the IL-15 activity”. This rejection can be overcome by deleting this limitation from the claim. Claim 5 recites the limitation "the Promega IL-15-bioassay" in line 3. There is insufficient antecedent basis for this limitation in the claim. Furthermore, it is unclear what “the Promega IL-15 bioassay” is and what the bioassay encompasses. Claim 5 is vague and indefinite because it recites the term “Promega“. Since this brand name has been trademarked, it should be recited with the appropriate ® symbol following the trademark. The presence of a trademark or trade name in a claim is not, per se, improper under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. MPEP § 608.01(v). PNG media_image1.png 18 19 media_image1.png Greyscale In the instant case, since the trademark or trade name is used in the claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of the 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. In fact, the value of a trademark would be lost to the extent that it became descriptive of a product, rather than used as an identification of a source or origin of a product. Thus, the use of the trademark or trade name in the claim to identify or describe a material or product renders the claim indefinite, but also constitutes an improper use of the trademark or trade name. See MPEP § 2173.05(u). Appropriate correction of the claim is requested. Claim 6, line 2, is vague and indefinite because it recites the limitation “and/or” and it is unclear what this limitation specifically encompasses. Does the IL-15 variant have or does it have not a substitution at position N77? Similarly, claim 7, lines 2, 5, 8, and 12, are vague and indefinite because it recites the limitation “and/or”. Claim 8 is vague and indefinite for several reasons. Claim 8 recites the limitation "the sushi domain" in line 2. There is insufficient antecedent basis for this limitation in the claim Claim 8, line 2, is vague and indefinite recites “IL-15Rα or a derivative thereof” and it is unclear how identical the “derivative” is to IL-15Rα. Is it 90%, 80% or even 60% identical? Claim 9 is rejected as vague and indefinite for several reasons. Claim 9, line 2, is grammatically incorrect because it recites “wherein in the fusion protein further comprises the sushi domain…”. Appropriate correction of the claim is required. Claim 9, lines 2-3, is vague and indefinite recites “IL-15Rα or a derivative thereof” and it is unclear how identical the “derivative” is to IL-15Rα. Is it 90%, 80% or even 60% identical? Claim 9, line 3, is vague and indefinite because it recites the limitation “and/or” and it is unclear what this limitation specifically encompasses. It is suggested that the claim be amended to recite “or a half-life extending domain” to obviate this rejection. Claim 10, line 2, is vague and indefinite because it recites “…and the IL-15 variant of, wherein the linker…” Appropriate correction of the claim is required to obviate this rejection. Claim 11, line 2, is vague and indefinite because it recites the limitation “antibody or functional variant thereof”. The metes and bounds of this limitation are unclear. What “function” of the “antibody” is encompassed by the claim? Furthermore, how identical is the “variant” to the antibody. Is it 90%, 80% or even 60% identical? Claim 18 recites the limitation "the IL-15Rα" in line 2. There is insufficient antecedent basis for this limitation in the claim Claims 3-4, and 16, are rejected as vague and indefinite insofar as they are dependent on the above rejected claims for their limitations. Conclusion No claim is allowed. Claims 1, 3-11, 16, 18 and 22 are rejected. Advisory Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to PREMA MARIA MERTZ whose telephone number is (571)272-0876. The examiner can normally be reached on Monday to Thursday from 7:30am to 6:00pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, VANESSA FORD, can be reached at telephone number 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /PREMA M MERTZ/ Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Dec 21, 2023
Application Filed
Oct 05, 2026
Examiner Interview (Telephonic)
Oct 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780918
Antigen Binding Proteins that Bind PD-L1
2y 9m to grant Granted Nov 03, 2026
Patent 12767723
TREATMENT FOR LUPUS NEPHRITIS USING ANTI-BAFFR ANTIBODIES
2y 11m to grant Granted Oct 20, 2026
Patent 12753217
IL-10 MUTEINS
4y 0m to grant Granted Oct 06, 2026
Patent 12735503
ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES
3y 0m to grant Granted Sep 15, 2026
Patent 12728169
IMMUNE CELL RECEPTOR ANTIBODIES CONJUGATED TO HIGH AFFINITY SIGLEC-LIGANDS
4y 4m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+34.6%)
2y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 774 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month